此次新任命的总裁，冯佶曾是一名神经科医生，后转型进入药企。 正在向港股上市冲刺的恒瑞医药（600276.SH），高层人事再度迎来调整。 而此次新任命的总裁冯佶，1970年生，曾是一名神经科医生，后转型进入药企。在加盟恒瑞医药之前， 她曾就职于上海仁济医院、诺华、安万特和阿斯利康，历经过不同的重要业务管理岗位，包括销售和营 销管理、事业部业务管理、全球产品组合战略及国际业务运营和拓展等重要业务管理工作。在阿斯利康 期间，先后担任阿斯利康中国区心血管药物业务单元副总裁、全球感染、中枢神经和自身免疫治疗领域 副总裁、中国区总经理、亚洲区区域副总裁、全球商业洞察与卓越业务高级副总裁等职务。 肿瘤领域是恒瑞医药的优势领域，但近年来，公司开始在代谢、自免等慢病领域发力。同时，恒瑞医药 也在加强国际化布局。冯佶在慢病领域的经验和资源，以及国际化背景，能否助力公司在非肿瘤领域和 国际市场进行快速拓展，是接下来的看点。 近年来，恒瑞医药已多次进行高管人员调整。据第一财经记者了解，目前其他主要高管的人员分工没有 太大变化：在以董事长孙飘扬的带领下，执行副总裁张连山仍坐镇创新药研发领域，执行副总裁江宁军 继续主管创新药国际化、临床 ...

以下文章来源于镁经 ，作者镁经小组 镁经 . 这是一个美丽又多金的公众号！新消费是我们的领地，擅长商业模式梳理，最爱发掘"美好生活新物种"。 如果您垂直细分、颜值高、易燃易爆炸，是冉冉 升起的网红品牌一枚，欢迎撩我！如果不行，我撩您。 （本公众号为"广州无冕信息技术有限公司"旗下账号。） 来源|镁经 作者|肖汝健 编辑|王大镁 作为A股功能性饮料龙头，东鹏特饮近两年经常因资本运作备受关注。 上市三年，其营收、净利润翻倍增长的同时，股东频繁套现与巨额分红也惹人关注。二股东靠减持累计套现超41亿元，创始人家族累计获得35亿元 分红。 更令人费解的是，这家手握142亿现金类资产的企业，一边大额理财、一边向银行借钱，还引发了不小的争议。 如今，它赴港二次上市的计划浮出水面，市场质疑声浪再起：这究竟是其国际化布局的资本跳板，还是股东套现的"第二通道"？ 01 一边是业绩狂飙，一边是频繁减持 对标红牛起家的东鹏特饮，如今成了名副其实的"造富机器"。 2021年5月上市后，东鹏的市值不断攀升，目前已突破1200亿元。这一市值，让东鹏饮料创始人林木勤以超510亿身家稳坐汕尾首富宝座。 千亿市值背后，是超预期的业绩增长。 数据 ...

Core Viewpoint - Guotai Junan Securities reported strong financial performance for 2024, with significant growth in both revenue and net profit, showcasing the resilience and innovative capabilities of leading brokerage firms [1][4]. Financial Performance - The total operating revenue for 2024 was 43.40 billion yuan, representing a year-on-year increase of 20.08% [2]. - The net profit attributable to shareholders reached 13.02 billion yuan, up 38.94% compared to the previous year [2]. - The net profit growth rate of 38.94% significantly outpaced the revenue growth of 20.08%, indicating improved operational efficiency and cost control [4]. Asset and Equity Growth - Total assets exceeded 1.05 trillion yuan, with a year-on-year growth of 13.22% [2]. - The net assets attributable to shareholders amounted to 170.77 billion yuan, reflecting a growth of 2.28% [2]. Shareholder Returns - The company plans to distribute a cash dividend of 2.8 yuan per 10 shares, totaling 4.92 billion yuan, which accounts for 48.05% of net profit, highlighting a commitment to shareholder returns [4]. Quarterly Performance - Quarterly operating revenues for 2024 were 7.98 billion yuan, 9.09 billion yuan, 11.93 billion yuan, and 14.40 billion yuan respectively [5]. - Quarterly net profits were 2.49 billion yuan, 2.53 billion yuan, 4.51 billion yuan, and 3.50 billion yuan respectively [5]. Business Segments - Brokerage business benefited from increased market trading volume, with net commission income rising by 15.51% [5]. - Investment income increased by 21.87 billion yuan, a growth of 20.15%, primarily due to higher returns from trading financial instruments [5]. - International subsidiary Guotai Junan International saw a revenue increase of 37% to 4.42 billion HKD, with net profit rising 73% to 348 million HKD [5].

Investment Rating - The investment rating for the company is "Buy" for both A-shares and H-shares, maintained from previous assessments [8]. Core Views - The company's revenue and net profit for 2024 are reported at 34.22 billion and 2.42 billion RMB, respectively, showing a year-on-year change of +1.4% and -12.5%. The Q4 results indicate a revenue of 9.50 billion RMB and a net profit of 1.28 billion RMB, with a notable increase in net profit by 43.9% year-on-year due to improved gross margins and asset disposal gains of 730 million RMB [1][2]. - The rebound in cement prices is expected to catalyze further recovery in profitability in Q1 2025, supported by international expansion and energy-saving initiatives driving long-term growth [1][4]. Revenue and Profitability - In 2024, the company sold 5.7 million tons of cement, 14.3 million tons of aggregates, and 3.2 million cubic meters of concrete, with year-on-year changes of -2.0%, +9.0%, and +16.7%, respectively. Revenue from these segments was 18.03 billion, 5.64 billion, and 8.42 billion RMB, showing changes of -1.6%, +5.2%, and +10.0% [2]. - The overall gross margin for 2024 was 24.7%, down 2.0 percentage points year-on-year, while Q4 gross margin was 26.4%, reflecting a slight improvement [2]. Cost Management and Cash Flow - The company's expense ratio for 2024 was 12.6%, a decrease of 0.3 percentage points year-on-year. The operating cash flow for 2024 was 5.98 billion RMB, down 4.1% year-on-year, but is expected to remain stable as cement business profitability improves [3]. International Expansion and Sustainability - The company's overseas revenue reached 8.04 billion RMB in 2024, a 46.5% increase year-on-year, with international business accounting for 23.5% of total revenue. The company has over 25 million tons of cement production capacity overseas [4]. - The company is committed to green and low-carbon development, achieving a reduction in domestic clinker energy consumption by 0.67 kgce/t in 2024 [4]. Earnings Forecast and Valuation - The earnings per share (EPS) estimates for 2025, 2026, and 2027 are projected at 1.19, 1.47, and 1.55 RMB, respectively. The target price for A-shares is raised to 15.83 RMB, based on a price-to-earnings (PE) ratio of 13.3x for 2025 [5]. - The target price for H-shares is adjusted to 11.74 HKD, reflecting a PE ratio of 9.2x for 2025, with a discount rate consistent with historical averages [5].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [4][12]. Core Insights - The company is acquiring 85% of REGEN Biotech, Inc. for $190 million, with the total equity valuation of the target company at approximately $224 million [1]. - The target company has two mature products and is expected to enhance the company's international market presence and product offerings [2][3]. - Revenue projections for the company are adjusted to reflect a net profit of 2.18 billion, 2.64 billion, and 3.14 billion RMB for 2024-2026, with respective year-on-year growth rates of 17%, 21%, and 19% [4][7]. Summary by Sections Acquisition Overview - The acquisition involves a cash investment of $190 million to acquire 85% of REGEN Biotech, which specializes in medical materials and devices [1]. - The target company has two operational factories in South Korea, with one factory expected to commence production in Q2 2025 [2]. Financial Projections - The company’s revenue is projected to grow from 2.87 billion RMB in 2023 to 4.67 billion RMB in 2026, reflecting a compound annual growth rate (CAGR) of approximately 18% [7]. - The diluted earnings per share (EPS) are forecasted to be 7.21, 8.73, and 10.38 RMB for 2024-2026 [4][7]. Market Positioning - The acquisition is expected to leverage the target company's market channels and brand influence to enhance the company's visibility in the global aesthetic medicine market [3]. - The core products of the target company complement the existing product line, potentially meeting diverse consumer needs [3].